sinc
decemb
coronaviru
diseas
spread
global
infect
million
peopl
caus
death
among
patient
especi
sever
critic
ill
varieti
potenti
risk
factor
venou
thromboembol
exist
includ
infect
immobili
sation
respiratori
failur
mechan
ventil
central
venou
cathet
use
howev
best
knowledg
risk
venou
thromboembol
patient
yet
report
use
nationwid
dataset
china
provid
delin
venou
thromboembol
risk
patient
behalf
nation
clinic
research
centr
respiratori
diseas
togeth
nation
health
commiss
peopl
republ
china
collect
data
patient
laboratoryconfirm
provinci
administr
region
throughout
countri
studi
support
nation
health
commiss
design
investig
approv
institut
review
board
nation
health
commiss
written
inform
consent
patient
waiv
light
urgent
need
collect
data
fact
retrospect
analysi
deidentifi
data
data
analys
interpret
author
continu
variabl
express
median
iqr
wilcoxon
ranksum
test
appli
continu
variabl
test
use
categor
variabl
estim
odd
ratio
associ
venou
thromboembol
risk
variabl
includ
outcom
laboratori
find
adjust
age
use
logist
regress
analys
logist
regress
venou
thromboembol
risk
evalu
admiss
hospit
via
padua
predict
score
data
patient
exclud
absenc
clinic
inform
patient
includ
consid
high
risk
basi
score
moreth
remain
patient
defin
low
risk
bleed
risk
evalu
accord
publish
investig
patient
consid
high
risk
two
risk
factor
age
year
older
hepat
failur
intern
normalis
ratio
sever
renal
failur
glomerular
filtrat
rate
mlmin
per
admit
intens
care
unit
coronari
care
unit
central
venou
cathet
diagnos
rheumat
diseas
activ
cancer
men
one
three
major
risk
factor
associ
bleed
activ
gastroduoden
ulcer
bleed
month
admiss
platelet
count
less
patient
high
risk
venou
thromboembol
older
like
high
risk
bleed
admit
intens
care
unit
mechan
ventil
die
result
complic
venou
thromboembol
patient
low
risk
venou
thromboembol
tabl
laboratori
find
admiss
show
patient
high
risk
venou
thromboembol
abnorm
concentr
aspart
aminotransferas
alanin
aminotransferas
creactiv
protein
patient
low
risk
adjust
age
appendix
patient
pneumonia
caus
pneumococc
influenza
infect
occurr
venou
thromboembol
shown
increas
although
know
number
patient
venou
thromboembol
cohort
patient
high
risk
estim
highrisk
patient
go
develop
venou
thromboembol
without
prophylaxi
data
n
median
iqr
adjust
age
risk
evalu
accord
previou
studi
threshold
year
select
basi
padua
predict
score
age
data
avail
patient
venou
thromboembol
event
prevent
appropri
prophylaxi
especi
highrisk
patient
howev
ten
patient
anticoagul
data
avail
cohort
receiv
anticoagul
drug
hospitalis
nine
given
heparin
one
rivaroxaban
lower
proport
proport
patient
high
risk
venou
thromboembol
find
could
suggest
venou
thromboembol
prophylaxi
adequ
cohort
patient
identifi
patient
high
risk
venou
thromboembol
provid
appropri
prophylaxi
therefor
import
anticoagul
drug
cornerston
venou
thromboembol
prophylaxi
howev
among
patient
high
risk
venou
thromboembol
cohort
also
high
risk
bleed
patient
dose
durat
anticoagul
adjust
mechan
compress
elast
compress
stock
intermitt
pneumat
compress
warrant
patient
rapidli
develop
sever
critic
diseas
caus
seri
complic
renal
failur
respiratori
failur
liver
dysfunct
affect
venou
thromboembol
bleed
statu
therefor
assess
venou
thromboembol
bleed
risk
regularli
essenti
addit
found
patient
high
risk
venou
thromboembol
poorer
outcom
patient
low
risk
suggest
patient
might
requir
increas
attent
case
rapid
deterior
